Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY3200882 in Participants With Solid Tumors
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.
Official title: A Phase 1 Study of LY3200882 in Patients With Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
223
Start Date
2016-11-21
Completion Date
2027-08
Last Updated
2026-04-03
Healthy Volunteers
No
Conditions
Interventions
LY3200882
Administered orally
LY3300054
Administered intravenously
Gemcitabine
Administered intravenously
nab-Paclitaxel
Administered intravenously
Cisplatin
Administered intravenously
Intensity Modulated Radiotherapy
Locations (18)
University of Louisville
Louisville, Kentucky, United States
Weill Cornell Medical College
New York, New York, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Calvary Mater Newcastle
Newcastle, New South Wales, Australia
St Vincent's Hospital Sydney
Sydney, New South Wales, Australia
Greenslopes Private Hospital
Greenslopes, Queensland, Australia
Princess Margaret Hospital (Ontario)
Lai Chi Kok, Kowloon, Canada
Hopital Saint-Louis
Paris, Cedex 10, France
CHRU de Lille
Lille, France
Gustave Roussy
Villejuif, France
Universitätsklinikum Würzburg A. ö. R.
Würzburg, Bavaria, Germany
Charité Campus Virchow-Klinikum
Berlin, Germany
Istituto Clinico Humanitas
Rozzano, Milano, Italy
Ospedale Policlinico Giambattista Rossi, Borgo Roma
Verona, Italy
National Cancer Center Hospital
Chuo-Ku, Tokyo, Japan
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain